Lenograstim-Induced Nodal Extramedullary Hematopoiesis: A Challenging Diagnosis in Lymphoma Evaluation With 18F-FDG PET/CT.
Fiche publication
Date publication
août 2020
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr NICOLAE Alina
Tous les auteurs :
Leroy-Freschini B, Nicolae A, Iltis-Roux A
Lien Pubmed
Résumé
We report the case of a 23-year-old man with nodal EMH (extramedullary hematopoiesis) occurring during treatment for a stage IIA "gray-zone" lymphoma. Although it is often related to myeloproliferative bone marrow disease, benign etiologies such as lenograstim treatment after chemotherapy can also induce EMH and be responsible for false-positive F-FDG PET/CT examinations. In this respect, GLUT overexpression in hematopoietic lineages and macrophages of the inflammatory environment are responsible for increased F-FDG uptake. Histopathologic confirmation of new hypermetabolic lesions on follow-up PET/CT may be required when the new lesions do not conform with the treatment responses in the preexisting lesions.
Mots clés
Fluorodeoxyglucose F18, Hematopoiesis, Extramedullary, drug effects, Humans, Lenograstim, adverse effects, Lymphoma, diagnostic imaging, Male, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Young Adult
Référence
Clin Nucl Med. 2020 Aug;45(8):e373-e375